31 October 2019 | News
Mesh Bio becomes the first Asian start-up to join the Batch 3 accelerator program to set pilot its digital health technology solutions and to make Singapore a gateway to Southeast Asia’s digital healthcare market
Photo credit: Mesh Bio
Mesh Bio, a Singapore-based predictive analytics digital health startup for diagnosis and management of chronic diseases, has announced its participation in the upcoming Startup Creasphere Batch 3 accelerator program, an international collaboration set to pilot Mesh Bio’s digital solutions.
Startup Creasphere is the first health innovation-focused accelerator in Munich, Germany. The program selects and empowers innovative health tech companies that hold immense potential to transform the current global healthcare ecosystem. Powered by Plug and Play, a leading global innovation platform and venture fund from Silicon Valley, and Roche, a global pioneer in pharmaceuticals and diagnostics, Startup Creasphere provides state-of-the-art infrastructure, bespoke programs and global networks to accelerate the success of promising health tech startups from around the world.
From hundreds of global applicants, Mesh Bio represents the only Asian company amongst the startups selected for this prestigious program. Mesh Bio’s participation in Startup Creasphere, puts Singapore on the global map in the digital health technology space. This recognition reinforces the government’s efforts to make Singapore a gateway to Southeast Asia’s digital healthcare market.
"Roche Diagnostics is a global leader in clinical diagnostics. We are privileged to be invited to participate in the Startup Creasphere digital health acceleration program. This program allows Mesh Bio to engage early with global healthcare leaders. It also gives us the opportunity to harness global knowledge and expertise to fine-tune our solutions for greater healthcare impact in chronic disease management,” said Dr Andrew Wu, co-founder and CEO of Mesh Bio.
Digital health has the potential to transform healthcare delivery for patients around the world. Asia is an important growth area, and effective chronic disease diagnosis and management is a key challenge for healthcare delivery. Startups with deep regional understanding, such as Mesh Bio, enables usage of innovative diagnostic tests to be tailored to the needs of providers and patients